748143-84-2

Upstream product

• 748143-81-9 (S)-2-Amino-N-[(S)-1-(4-chloro-benzyl)-2-ethylcarbamoyl-2-hydroxy-ethyl]-3-methyl-butyramide 
• 14631-30-2 2-(5-(1,2-dithiolane-3-yl)pentanamido)acetic acid 
• 748143-83-1 C₁₉H₂₉ClN₄O₄ 
• 1077-28-7 Thioctic acid 
• 51301-86-1 Boc-p-chloro-L-Phe-OH 
• 908342-71-2 2-tert-butoxycarbonylamino-3-methyl-butyric acid 2-tert-butoxycarbonylamino-3-(4-chloro-phenyl)-1-ethylcarbamoyl-propyl ester 
• 322392-25-6 tert-butyl (S)-(1-(4-chlorophenyl)-3-oxopropan-2-yl)carbamate 
• 322392-24-5 [2-(4-chloro-phenyl)-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy

Dipeptide-derived α-keto-amide compounds with potent calpain inhibitory activity have been identified. These reversible covalent inhibitors have IC50 values down to 25 nM and exhibit greatly improved activity in muscle cells compared to the reference compound MDL28170. Several novel calpain inhibitors have shown positive effects on histological parameters in an animal model of Duchenne muscular dystrophy demonstrating their potential as a treatment option for this fatal disease.

Alpha-Keto carbonyl calpain inhibitors

The present invention relates to novel α-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse at